Growth Hormone & PerformanceGrade B
CJC-1295
A GHRH analog that raises baseline GH and IGF-1, frequently paired with a ghrelin agonist such as ipamorelin.
- Regulatory status
- Not approved
- Half-life
- ~30 min (no DAC) / ~6–8 days (DAC)
- Route
- Subcutaneous
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Modified GHRH (1-29) resistant to enzymatic breakdown; the DAC version binds albumin for week-long activity.
Studied and reported uses
- GH/IGF-1 support
- Body composition
- Recovery
Dosing information
No-DAC100 mcg daily, often with ipamorelin
With DAC1–2 mg weekly
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Flushing
- Injection-site redness
- Edema
- Joint discomfort
Research evidence
Phase 1/2
Dose-dependent IGF-1 elevation for up to 14 days.